Je was op zoek naar: randomized (Engels - Maltees)

randomized
randomizzata

randomized trial
prova aleatorja

all randomized e:
kollha randomized e:

randomized clinical trial
prova klinika aleatorja

features of randomized patients
karatteristiċi tal-pazjenti randomizzati

patients were randomized to receive uc
il- pazjenti kienu randomized biex jirċievu interferon alfa- 2b pegilat (1. 5 µg/ kg/ ġimgħa) flimkien ma ’ ribavirin (800 mg/ jum) jew inkella viraferon (3 miu tiw) flimkien ma ’ ribavirin ina

the patients were randomized to carbamazepine cr
il-pazjenti kienu magħżula b’mod każwali biex jieħdu jew carbamazepine cr

mean age of subjects randomized was 49 years.
l-età medja tal- individwi magħżula b’mod każwali kienet ta’ 49 sena.

a meta-analysis of randomized placebo-controlled
meta- analiżi ta ’ provi randomized u kkontrollati mill- plaċebo ta ’ mediċini ta ’ kontra l- epilessija juri żieda żgħira fil- ħsibijiet u mġieba suwiċidali.

subjects randomized to receive erythropoietin (n=251)
individwi li ntgħażlu b’mod każwali biex jirċievu erythropoietin (n=251)

table 2: efficacy results in randomized clinical studies
tabella 2: riżultati tal-effikaċja fi studji kliniċi randomizzati

1 itt (intent to treat population): all randomized patients
1 itt (popolazzjoni b’intenzjoni li tiġi kkurata): pazjenti li kollha ntgħażlu b’mod każwali

at the time of the primary analysis there were 1633 patients randomized.
fiż-żmien tal-analiżi primarja kien hemm 1633 pazjent magħżula b’mod każwali.

hba1c subgroup analysis by baseline hba1c at week 24 in randomized subjects
analiżi tas-sottogrupp ta' hba1c permezz tal-linja bażi ta' hba1c fil-ġimgħa 24 f'individwi randomizzati

table 2 summary of overall survival (all patients as randomized)
tabella 2 sommarju tas-sopravivenza ġenerali (il-pazjenti kollha kif imqassma b'mod aleatorju)

group # responders / # randomized hazard ratio (95% ci)
grupp # ta’ persuni li kellhom rispons / # ta’ parteĊipanti li ntgĦaŻlu b’mod kaŻwali proporzjon ta’ periklu (95 % ci)

however two of the randomized patients discontinued the study before receiving any study treatment
madankollu tnejn mill-pazjenti randomised waqfu mill-istudju qabel ma rċevew kwalunkwe trattament tal-istudju

a total of 350 patients were randomized (randomization ratio 1:1).
b’mod arbitrarju ntagħażlu total ta’ 350 pazjent (proporzjon ta’ randomizzazzjoni ta’ 1:1).

a randomized double-blind placebo controlled study was conducted in 83 patients with fap.
sar studju b’mod każwali fejn la t-tabib u lanqas il-pazjent ma kienu jafu x’qed jingħata, ikkontrollat bil-plaċebo fi 83 pazjent bl-fap.

60 patients were randomized and treated, and 60/60 (100%) achieved svr12.
60 pazjent kienu randomizzati u trattati, u 60/60 (100%) kisbu svr12.